Silicon Valley billionaire Sean Parker — the founder of Napster and an early investor in Facebook — pledged $250 million in 2016 to bring together researchers from academic cancer centers across the country with the goal of accelerating the development of new treatments that harness the immune system to attack cancer.
On Sunday, the Parker Institute for Cancer Immunotherapy is presenting clinical trial results for the first time. And those results, which come just a year and a half after the first patient was enrolled in the study, show tumor shrinkage from the multi-drug regimen administered to patients with metastatic pancreatic cancer.
The new findings from the Phase 1 clinical trial were unveiled at the American Association of Cancer Research annual meeting underway in Atlanta.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect